SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Jakob Dupont, its Executive Vice President, Global Head of Research & Development.
The compensation committee of Atara’s board of directors granted Dr. Dupont restricted stock units to acquire 46,250 shares of Atara’s common stock under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, effective as of May 14, 2020. The restricted stock units were granted as an inducement material to Dr. Dupont entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The compensation committee also granted Dr. Dupont a stock option to purchase 277,500 shares of Atara’s common stock under the Atara Biotherapeutics, Inc. 2014 Equity Inventive Plan, as amended, effective as of May 14, 2020. The stock option has a ten-year term and an exercise price of $9.58, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 14, 2020.
The awards vest over four years, with 25 percent vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming Dr. Dupont is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other severe diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.